# A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

> **NCT02098967** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 68 (actual)

## Conditions studied

- Neoplasms, Myelogenous Leukemia, Acute

## Interventions

- **DRUG:** RO6839921
- **DRUG:** RO6839921
- **DRUG:** RO6839921

## Key facts

- **NCT ID:** NCT02098967
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-21
- **Primary completion:** 2018-05-07
- **Final completion:** 2018-05-07
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098967, "A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02098967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*